Results 211 to 220 of about 1,011,686 (269)

IGSF9-targeted therapy inhibits the progression of acute myeloid leukemia. [PDF]

Blood Adv
Hui L, Xiao J, Zhao Z, Zhang J, Luan H, Zhang J, Sun Y, Meng X, Wang H, Li C, Li F, Ji S, Wei S, Li F, Yu H, Zheng C, Jiang Y, Wang Y, Li Z.   +18 more
europepmc   +1 more source

Indoleamine 2,3‐dioxygenase 1 inhibition reverses cancer‐associated fibroblast‐mediated immunosuppression in high‐grade serous ovarian cancer

FEBS Open Bio, EarlyView.
CAF‐mediated immunosuppression in ovarian cancer is driven by IDO1, reducing T‐cell function. Inhibiting IDO1 restores T‐cell proliferation and cytotoxicity, increases cancer cell apoptosis, and may help overcome CAF‐induced immune suppression in high‐grade serous ovarian cancer. Targeting IDO1 may improve antitumor immunity.
Hyewon Lee, Jung Yoon Ho, In Sun Hwang, Youn Jin Choi   +3 more
wiley   +1 more source

HSP70 governs permeability and mechanotransduction in primary human endothelial cells

FEBS Open Bio, EarlyView.
HSP70 chemical inhibition reduces endothelial cell proliferation and increases permeability, the latter supported by normal interendothelial junctional protein distribution. HSP70 also plays a role in shear stress response, a hemodynamic force naturally present in blood vessels and correlated with vessel protection.
Andrea Pinto‐Martinez, Everton G. Melo, Isadora C. B. Pavan, Percíllia V. S. Oliveira, Luiza B. C. T. Coimbra, Thaís L. S. Araujo   +5 more
wiley   +1 more source

MicroRNAs in breast cancer-new frontiers in diagnosis, targeted therapy, and prognosis assessment. [PDF]

Front Oncol
Xiao J, Zhang L, Su R, Zhao B, Dang Y, Zhao C, Wang S, Qi T, Ji F.   +8 more
europepmc   +1 more source

Thrombolytic proteins profiling: High‐throughput activity, selectivity, and resistance assays

FEBS Open Bio, EarlyView.
We present optimized biochemical protocols for evaluating thrombolytic proteins, enabling rapid and robust screening of enzymatic activity, inhibition resistance, and fibrin affinity, stimulation, and selectivity. The outcome translates to key clinical indicators such as biological half‐life and bleeding risk. These assays streamline the development of
Martin Toul, Alan Strunga, Jiri Damborsky, Zbynek Prokop   +3 more
wiley   +1 more source

Resistance Mutations in CLL: Genetic Mechanisms Shaping the Future of Targeted Therapy. [PDF]

Genes (Basel)
Sekeres S, Lamkin EN, Bravo E, Cool A, Taylor J.   +4 more
europepmc   +1 more source

Targeting neuronal nitric oxide synthase as a valuable strategy for the therapy of neurological disorders

, 2016
Cristina Maccallini, Rosa Amoroso
openalex   +1 more source

Molecular determinants of signal transduction in tropomyosin receptor kinases

FEBS Open Bio, EarlyView.
Tropomyosin receptor kinases control critical neuronal functions, but how do the same receptors produce diverse cellular responses? This review explores the structural mechanisms behind Trk signaling diversity, focusing on allosteric modulation and ligand bias.
Giray Enkavi
wiley   +1 more source

Datopotamab deruxtecan: a new era in targeted therapy for metastatic breast cancer. [PDF]

Ann Med Surg (Lond)
Mobashir M, Tarique H, Ahmad S, Habib I, Inam A, Qamar I, Sajjad W.   +6 more
europepmc   +1 more source

Targeting tropomyosin receptor kinase for cancer therapy

, 2019
Qi Miao, Kun Ma, Dong Chen, Xiaoxing Wu, Sheng Jiang   +4 more
openalex   +1 more source